Lonza
Biologics

Can You Predictably Manage

Your Drug Development Budget and Timeline?

The Challenge:

Staying On Time and On Budget Despite So Many Choices

It's not enough that drug development is a long, complicated process. You're seeing this challenge compounded by the need for more complex and difficult-to-express molecules to address a variety of diseases, older patients, and multiple comorbidities.

Different approaches have risks

You may be working with multiple suppliers and partners to try to achieve your milestones on time. But the challenges inherent in managing multiple vendors and linking up timelines and material availability can create unacceptable delays in your process, forcing you to miss key milestones.

Alternatively, you may focus on areas where you have internal expertise, paying less attention to those you're less familiar with. However, that scenario can create undesirable impacts on your timelines and budgets, too.

Fortunately, Lonza's Bench-to-Clinic solution offers a better way to overcome this challenge.

Fortunately, Lonza's Bench-to-Clinic solution **offers a better way** to overcome this challenge.

Match Your Molecule to **the Right Development Platform**

Creating cell lines with speed, efficiency, and scalability is critical to your success. With Lonza, you'll have customized solutions and services designed to meet your unique gene-to-IND needs and risk tolerance. You'll be assured a solution that matches your needs in terms of molecule type, and go from gene to IND using an approach built specifically to support your goals.

By doing so, you'll begin clinical trials as fast as technically possible, with complete support to overcome any issues you may encounter on the way. Through this approach, your overall spend will be less and your timeline will be shorter. Ultimately, you'll meet both your company's and investors' expectations while maximizing your asset's value so you can move to the next milestone and round of funding.

When you **match your molecule** to the right development approach, you can meet investor's expectations and maximize your asset's value.

Complete Gene to IND CMC With **Guaranteed Timeline and Drug Substance Quantity**

Moving from gene to IND may seem straightforward, but missed milestones and re-work often complicate your path and endanger your success. With Lonza, you can take advantage of Ibex® Design, a fixed scope gene to IND offering that delivers GMP drug product for your clinical phase 1 trials in 12 months, with an option to supply tox drug product in only nine months. You'll be well equipped to speed your milestones, as Lonza guarantees the timelines of the product supplied—and commits to a minimum quantity of 1.5 kg GMP drug substance that is vialled for your phase 1 clinical needs at a fixed cost for antibodies and antibody-like molecules.

You'll gain clarity and reduce uncertainty with a program that offers development and a completed IND package within one year. You'll complete critical CMC activities on your IND application path as quickly as possible. You'll also count on predictable clinical supply and costs, which further streamlines production and planning.

With contractual commitments tied to time and quantity, you'll confidently plan on reaching your clinical trial on time and within budget.

Progress Molecules While Completing Funding Activities

By their very nature, biotechs are both mindful of cash flow challenges and focused on getting the maximum advantage from every dollar they spend. With Lonza, you'll be able to take advantage of alternative commercial solutions designed to support different customers' financial and technical needs.

Thanks to the availability of various program approaches and business models, you can more easily customize a plan that aligns with your specific needs. For instance, you may create a staged approach that gets you to RCB, or choose from among different options for tailored payment plans or performance-based pricing.

Working with Lonza, you can more **easily customize a plan** that aligns with your program needs.



When You Implement Lonza's Bench-to-Clinic Solution, You Will...

Match your molecule to the right development platform

Complete gene to IND CMC with guaranteed timeline and drug substance quantity

Progress molecules while completing funding activities

Learn how

you can maximize your asset value without the fear that funding will run out.
Visit us at **Bench to Clinic | Lonza**.

Leading companies have simplified their clinical CMC journey by choosing Lonza early as their sole, full-service development partner. Because Lonza solves early-stage challenges—from de-risking and optimizing lead candidates to accelerated timelines—and has line of sight to later-stage clinical and commercial goals, you're able to experience enhanced compounding benefits in terms of speed, reduced risk and complexity, and ultimately lower costs.

Lonza
Biologics